Enabling Wider Antigen Selection With Logic-Gated CAR T-Cell Therapy for Solid Tumors
Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.
Ben Creelan, MD, on the Potential of Logic-gated Tmod CAR-T in Lung Cancer and Other Solid Tumors
The medical oncologist at Moffitt Cancer Center spoke about A2 Bio’s A2B530 as part of a larger discussion of novel cell therapy approaches in solid tumors.
Novel Approaches to Cell Therapy May be Necessary to Tackle Non–Small Cell Lung Cancer
Ben Creelan, MD, a medical oncologist at Moffitt Cancer Center, discussed several different approaches to cell therapy that could lead to new treatment options in the field.
Maria Pia Morelli, MD, PhD, on Logic-Gated CAR Targeting of Solid Tumors
The assistant professor at MD Anderson Cancer Center discussed the EVEREST-1 clinical trial of A2B530.
BASECAMP-1 Trial Identifies Patients With Solid Tumors to Assess Novel CAR T-Cell Therapy
J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
Kedar Kirtane, MD, on CAR T-Cell Agent A2B530 and Its Unique Approach to Solid Tumors
The assistant member in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center spoke about A2B530's mechanism of action and how it could represent a leap forward in the application of CAR T-cell agents for patients with solid tumors.
Identifying Patients for EVEREST-1 Trial of CAR T-Cell Therapy in Solid Tumors
Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert, diving into the unique mechanism of action of A2B530.
Harnessing a Unique Approach With A2B530 to Bring CAR T Treatment to Solid Tumors
The BASECAMP-1 clinical trial will aim to find patients with advanced solid tumors who are good candidates for the subsequent EVEREST trial.
EVEREST-1 Trial in Solid Tumors Doses First Patient With A2B530
The autologous CAR T-cell therapy A2B530 is being investigated for solid tumors in the multicenter, first-in-human, phase 1/2 EVEREST-1 study.
Bringing HLA-A*02-directed CAR T to Solid Tumor Care With the EVEREST-1 Trial
Diane M. Simeone, MD, discussed the phase 1/2 EVEREST-1 trial, which seeks to assess the novel CAR T-cell therapy A2B530 in patients with solid tumors—hopefully progressing one-and-done engineered therapies in this population.
BASECAMP-1: Trial of Novel CAR T-Cell Agent Seeks Patients Eligible for Treatment
Investigators have initiated the BASECAMP-1 trial of investigational agent A2B530 with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial.
2 Clarke Drive Cranbury, NJ 08512